Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of September 1, 2026, RGEN trades at $180.98 with a market cap of $9.95B and a P/E ratio of 237.55. RGEN moved +2.58% today. Year to date, RGEN is +10.45%; over the trailing twelve months it is +47.96%. Its 52-week range spans $100.99 to $188.73. Analyst consensus is strong buy with an average price target of $173.82. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for RGEN, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $180.98 |
| Market Cap | $9.95B |
| P/E Ratio | 237.55 |
| EPS | $0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $188.73 |
| 52-Week Low | $100.99 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $785.10M |
| Net Income | $41.54M |
| Gross Margin | 53.84% |
13 analysts cover RGEN: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $173.82.